

Case IPR2018-00943  
Patent No. 7,919,499  
Declaration of Sara K. Quinney, Pharm.D., Ph.D.  
Attorney Docket No. AMNEAL 7.1R-005

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC,  
Petitioner,

v.

ALKERMES PHARMA IRELAND LIMITED,  
Patent Owner.

Patent No. 7,919,499 to Elliot Ehrich  
Issue Date: May 19, 2015  
Title: NALTREXONE LONG ACTING  
FORMULATIONS AND METHODS OF USE

---

*Inter Partes* Review No. IPR2018-00943

---

**(Exhibit 1062)**

**DECLARATION OF SARA K. QUINNEY, Pharm.D., Ph.D. IN SUPPORT  
OF PETITIONER'S REPLY TO PATENT OWNER'S RESPONSE**

**TABLE OF CONTENTS**

	Page
I. INTRODUCTION .....	2
II. BACKGROUND AND QUALIFICATIONS .....	2
III. SUMMARY OF OPINIONS .....	8
IV. BACKGROUND ON PHARMACOKINETICS .....	9
V. A PERSON OF ORDINARY SKILL IN THE ART .....	15
VI. THE '499 PATENT .....	16
A. The Claimed AUC Differential Is Not Unexpected .....	17
B. The Claimed AUC Differential Is Not Correlated To Improved Therapeutic Effects .....	19
VII. AUC AND METHODS OF CALCULATION .....	21
A. The Area Under The Curve (AUC) .....	21
B. Use Of Photoshop To Calculate AUC .....	25
VIII. AUC AND PK DATA SETS .....	28
A. AUC Calculations And Time Zero .....	28
B. AUC And Plasma Level .....	33
C. AUC And Prior Administration .....	40
D. A POSA Would Recognize The Data Sets Of Comer And Nuwayser As Originating From The Same Study .....	47
IX. CONCLUSION .....	49

I, SARA K. QUINNEY, declare and state as follows:

**I. INTRODUCTION**

1. I am a U.S. Citizen and a resident of the State of Indiana.

2. I have been retained by Lerner, David, Littenberg, Krumholz & Mentlik, LLP (“counsel”) to provide my opinions in the field of clinical pharmacology and pharmacokinetics for purposes of this *Inter Partes* Review (“IPR”). I have read and understand U.S. Patent No. 7,919,499 (“the ’499 Patent”) (Ex. 1001) as well as all other references discussed in this declaration. I am being compensated for my time in an amount consistent with my customary consulting fee, and my compensation is not contingent on my opinion or the outcome of this proceeding.

**II. BACKGROUND AND QUALIFICATIONS**

3. I am an expert in pharmacokinetics, which is frequently abbreviated as “PK.” Pharmacokinetics is the branch of pharmacology that describes and quantifies the movement of a drug within the body of a living organism. Pharmacokinetics provides information on mechanisms of drug absorption, distribution, metabolism, excretion, and transport (ADMET). My background and qualifications are set forth in my *curriculum vitae*. (Ex. 1063.) It contains a description of my education, academic appointments, professional activities, research grants, presentations, service as a reviewer for professional journals,

published articles in peer reviewed scholarly journals, teaching responsibilities, and thesis supervision.

4. I hold a primary appointment as an Assistant Professor of Obstetrics and Gynecology at Indiana University School of Medicine (IUSM). Additionally, I hold adjunct appointments in the Division of Clinical Pharmacology, Department of Medicine in IUSM, the School of Informatics and Computing at Indiana University Purdue University Indianapolis (IUPUI), and the Department of Pharmacy Practice, College of Pharmacy, Purdue University.

5. I am the Associate Director of the Indiana Clinical and Translational Sciences Institute (CTSI) Disease and Therapeutic Response Modeling Program. This program provides training in pharmacometrics and quantitative systems pharmacology, including pharmacokinetic/pharmacodynamic (PK/PD) modeling, physiologically based pharmacokinetic (PBPK) modeling, and machine learning. I am also a member of the Center for Computational Biology and Bioinformatics (CCBB) at the Indiana University School of Medicine.

6. I obtained my Doctorate in Pharmacy from Purdue University in 2000 and obtained my Ph.D. in Pharmacy Practice from Purdue University in 2004. I subsequently completed a Postdoctoral Fellowship in Clinical Pharmacology at the Indiana University Division of Clinical Pharmacology in 2007 and completed a Postdoctoral Fellowship in Bioinformatics and Biostatistics at the Indiana

University Department of Biostatistics in 2009. I joined the Indiana University School of Medicine as an Assistant Research Professor in 2009, and since 2013, I have been an Assistant Professor in the Division of Clinical Pharmacology and in the Department of Obstetrics and Gynecology at the Indiana University School of Medicine. Since 2013, I have also been a member of the Center for Computational Biology and Bioinformatics and since 2015, I have been an Associate Director of the Indiana CTSI Disease and Therapeutic Modeling Program within the Indiana University School of Medicine.

7. Since 2009, I have designed and directed a number of clinical PK studies, primarily in pregnant women. For instance, I conducted a PK study to evaluate the effect of pregnancy on the PK of nifedipine administered to women with preterm labor. In collaboration with other investigators at IUSM, I have evaluated the impact of pharmacogenomic variants in CYP3A enzymes on the PK and PD of betamethasone for fetal lung maturation. I am currently conducting a study in women in their third trimester of pregnancy to evaluate the effect of hepatitis C virus (HCV) on the clearance of buprenorphine. Therefore, I am well versed in the design and conduct of clinical pharmacology studies, especially studies of PK, PD, and pharmacogenomics.

8. My research also encompasses the area of opiate use disorder. I have conducted a clinical study evaluating the relationship between exposure of R- and

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.